Immunotherapeutic approaches, particularly programmed death 1/programmed death ligand 1 (PD-1/PD-L1) blockade, have improved the treatment of non-small-cell lung cancer (NSCLC), supporting the premise that evasion of immune destruction is of importance for NSCLC progression. However, the signals responsible for upregulation of PD-L1 in NSCLC cells and whether they are integrated with the regulation of other immune-related genes are not known. Mucin 1 (MUC1) is aberrantly overexpressed in NSCLC, activates the nuclear factor-κB (NF-κB) p65 → ZEB1 pathway and confers a poor prognosis. The present studies demonstrate that MUC1-C activates PD-L1 expression in NSCLC cells. We show that MUC1-C increases NF-κB p65 occupancy on the CD274/PD-L1 promoter and thereby drives CD274 transcription. Moreover, we demonstrate that MUC1-C-induced activation of NF-κB → ZEB1 signaling represses the TLR9 (toll-like receptor 9), IFNG, MCP-1 (monocyte chemoattractant protein-1) and GM-CSF genes, and that this signature is associated with decreases in overall survival. In concert with these results, targeting MUC1-C in NSCLC tumors suppresses PD-L1 and induces these effectors of innate and adaptive immunity. These findings support a previously unrecognized central role for MUC1-C in integrating PD-L1 activation with suppression of immune effectors and poor clinical outcome.
INTRODUCTION
A hallmark of human cancers is the evasion of immune destruction. 1 Cancers are often infiltrated with immune cells that are ineffective in recognizing tumor antigens. 2 In this way, immunotherapy has recently changed the landscape of nonsmall-cell lung cancer (NSCLC) treatment. 3 Blockade of the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) immune checkpoint, in particular, is broadly effective in the treatment of NSCLCs and can extend survival in patients with tumors not responsive to targeted therapy. However, PD-1/PD-L1 blockade is associated with a response rate of~20% in NSCLC and these responses are often of short duration. 3 These findings have supported the premise that evasion of immune recognition and destruction contributes to the pathogenesis of NSCLC and that additional approaches are needed to enhance the effectiveness of PD-1/PD-L1 blockade. 4, 5 Studies in genetically engineered mouse models have demonstrated that NSCLCs driven by mutant EGFR (epidermal growth factor receptor) activate the PD-1/PD-L1 pathway and thereby suppress T-cell function. 6 KRAS-driven NSCLCs also increase inflammatory cytokine production to suppress T-cell activity in the tumor microenvironment. 7 However, the signaling pathways responsible for regulating PD-L1 expression and other immune-related genes in NSCLC cells remain largely unknown.
Mucin 1 (MUC1) is a transmembrane glycoprotein that is aberrantly overexpressed in 480% of NSCLCs. 8 Moreover, the overexpression of MUC1 in NSCLCs is associated with a poor disease-free and overall survival. [8] [9] [10] [11] [12] [13] The frequency of mutations in the MUC1 gene is low (~1%) in NSCLCs compared with that for EGFR, KRAS and p53, [14] [15] [16] emphasizing the importance of aberrant MUC1 expression, rather than mutational activation, for NSCLC pathogenesis. MUC1 consists of two subunits: an N-terminal extracellular mucin subunit (MUC1-N) and a transmembrane C-terminal subunit (MUC1-C) that functions as an oncoprotein. 17, 18 MUC1-C includes a 58-amino-acid extracellular domain, which forms complexes with galectin-3 and thereby cell surface receptor tyrosine kinases, such as EGFR. 19 The MUC1-C 72-amino-acid cytoplasmic domain is an intrinsically disordered structure, 20 which has the plasticity to interact with multiple kinases and effectors that have been linked to transformation. 17, 18 In this context, MUC1-C directly activates the TAK1 → IKK → NF-κB p65 pathway, linking this inflammatory response to epithelial-tomesenchymal transition (EMT) and self-renewal of cancer cells. [21] [22] [23] The pleotropic activities of the MUC1-C subunit are dependent on a CQC motif in the cytoplasmic domain that is necessary and sufficient for the formation of MUC1-C homodimers and their import into the nucleus. 20, 24, 25 Accordingly, inhibitors of MUC1-C, such as GO-203, target the CQC motif and block MUC1-C homodimerization. 26 In this way, the effects of GO-203 on NSCLC cells are phenocopied by MUC1-C silencing and expression of a dominant-negative MUC1-C(CQC → AQA) mutant. [26] [27] [28] The present studies demonstrate that targeting MUC1-C in NSCLC cells is associated with the downregulation of PD-L1 expression. We show that MUC1-C induces CD274 transcription by an NF-κB p65-dependent mechanism. Our results further demonstrate that activation of a MUC1-C → NF-κB → ZEB1 pathway results in repression of TLR9 (toll-like receptor 9), IFNG, MCP-1/CCL2 and GM-CSF/CSF2 gene expression. These previously unexplored findings support a model in which MUC1-C has a central role in integrating the induction of PD-L1 with suppression of genes encoding effectors of innate and adaptive immunity.
RESULTS

MUC1-C drives PD-L1 expression in NSCLC cells.
Targeting MUC1-C in H1975/EGFR(L858R/T790M) NSCLC cells is associated with suppression of EGFR activation. 27 In the present work, we found that silencing MUC1-C in H1975 cells also results in the downregulation of PD-L1 mRNA (Figure 1a , left) and protein (Figure 1a , right). Other works have shown that MUC1-C confers EMT and self-renewal capacity in A549/KRAS(G12S) and H460/ KRAS(Q61H) cells. 28 To extend these observations to KRAS mutant NSCLC cells, we silenced MUC1-C in H460 cells and found downregulation of PD-L1 expression ( Figure 1b , left and right). Similar results were obtained with A549 cells (Figure 1c , left and right), indicating that stable silencing of MUC1-C in both EGFR and KRAS mutant NSCLC cells decreases PD-L1 expression. To confirm these findings, we established A549 cells stably expressing a tetracycline-inducible tet-on control short hairpin RNA (tet-CshRNA) or a MUC1shRNA (tet-MUC1shRNA). Treatment of A549/tet-CshRNA cells with doxycycline for 7 days had no apparent effect on MUC1-C or PD-L1 expression (Figure 1d , left). By contrast, treatment of A549/tet-MUC1shRNA cells resulted in suppression of MUC1-C, as well as PD-L1, expression ( Figure 1d , right). In further support of a MUC1-C → PD-L1 pathway, enforced overexpression of MUC1-C in H1975 ( Figure 1e ) and H460 ( Figure 1f ) cells was associated with the upregulation of PD-L1, indicating that MUC1-C is sufficient for this response. These results supported the premise that MUC1-C is necessary for PD-L1 expression in NSCLC cells.
Targeting the MUC1-C cytoplasmic domain downregulates PD-L1 expression MUC1-C includes a 58-amino-acid extracellular domain, a 28-amino-acid transmembrane domain and a 72-amino-acid cytoplasmic domain (Figure 2a ). The MUC1-C cytoplasmic domain contains a CQC motif that is necessary for MUC1-C homodimerization, nuclear localization and function as an oncoprotein (Figure 2a ). 18, 29 In this respect, expression of a MUC1-C(CQC → AQA) mutant in NSCLC cells blocks anchorage-independent growth and tumorigenicity, supporting a dominant-negative effect. [27] [28] [29] In addition, we found that stable expression of the MUC1-C(CQC → AQA) mutant in H1975 ( Figure 2b ) and H460 ( Figure 2c ) cells results in suppression of PD-L1 expression, further indicating that the MUC1-C cytoplasmic domain confers this response. Targeting the MUC1-C CQC motif with the cellpenetrating peptide, GO-203, blocks MUC1-C homodimerization and signaling in NSCLC cells. [26] [27] [28] has been recently formulated in polymeric nanoparticles (NPs) for more effective intracellular delivery to cancer cells growing in mouse models. 30 Treatment of H1975 and H460 cells with GO-203/NPs, but not empty NPs, was associated with the downregulation of PD-L1 expression (Figures 2d and e ). Moreover, studies of H1299 NSCLC cells, which express wild-type EGFR and KRAS, 31 demonstrated that GO-203/NP treatment decreases PD-L1 expression ( Figure 2f ), indicating that the effect of targeting MUC1-C on PD-L1 repression is independent of the mutational status. GO-203/NP treatment of immunocompromised nude mice bearing H460 tumor xenografts was associated with inhibition of growth ( Figure 2g ), consistent with decreases in self-renewal, 28 and also suppression of PD-L1 mRNA and protein ( Figure 2h , left and right). These findings demonstrate that MUC1-C is a target for downregulating PD-L1 in NSCLC cells. The results (mean ± s.e.m. of three biological replicates each performed in triplicate) are expressed as relative mRNA levels compared with that obtained with cells expressing CshRNA (assigned a value of 1). Lysates were immunoblotted with the indicated antibodies (right). (d) A549 lung cancer cells were transfected to stably express an inducible control shRNA (left) or MUC1shRNA (right). After treatment with doxycycline (DOX) for 72 h, lysates from the indicated cells were immunoblotted with antibodies against MUC1-C, PD-L1 and β-actin.
(e, f) H1975 (e) and H460 (f) cells were transiently transfected to express an empty vector or MUC1-C for 72 h. MUC1 (left) and PD-L1 (right) mRNA levels were determined by qRT-PCR. The results (mean ± s.e.m. of three biological replicates each performed in triplicate) are expressed as relative mRNA levels as compared with that obtained for cells expressing the empty vector (assigned a value of 1).
MUC1-C drives CD274/PD-L1 transcription by an NF-κB p65-dependent mechanism To define the mechanism by which MUC1-C drives PD-L1 expression, we first transfected H1975/CshRNA and H1975/ MUC1shRNA cells with a CD274 promoter-luciferase reporter (pPD-L1-Luc; Figure 3a ). The experiment revealed that silencing MUC1-C decreases pPD-L1-Luc activity (Figure 3b ). Similar results were obtained in H460 ( Figure 3c ) and A549 (Supplementary Figure S1A ) cells, indicating that MUC1-C induces CD274 transcription. Along these lines, expression of the MUC1-C(CQC → AQA) mutant in H1975 (Supplementary Figure S1B ) and H460 (Supplementary Figure S1C ) cells also suppressed CD274 promoter activity. MUC1-C activates the inflammatory TAK1 → IKK → NF-κB p65 pathway. [21] [22] [23] Accordingly, we asked if treatment of NSCLC cells with Bay-11-7085, an irreversible inhibitor of IκBα phosphorylation, affects PD-L1 expression. Using this approach, we found that inhibiting the NF-κB pathway in H1975 ( Figure 3d The MUC1-C cytoplasmic domain contains a CQC motif that is necessary and sufficient for MUC1-C homodimerization and oncogenic function. GO-203 is a cell-penetrating peptide that targets the CQC motif and blocks MUC1-C homodimerization. GO-203 has been encapsulated into NPs (GO-203/NPs) for delivery in mouse tumor models. The MUC1-C cytoplasmic domain binds directly to IKKβ, IKKγ and NF-κB p65 and promotes the activation of NF-κB target genes. (b, c) H1975 (b) and H460 (c) cells were infected with lentiviral vectors to stably express an empty vector or MUC1-C(AQA). The indicated cells were analyzed for PD-L1 mRNA levels by quantitative real-time, reverse transcriptase PCR (qRT-PCR). The results (mean ± s.e.m. of three biological replicates each performed in triplicate) are expressed as relative PD-L1 mRNA levels as compared with that obtained for the vector cells (assigned a value of 1).
(d-f) H1975 (d), H460 (e) and H1299 (f) cells were treated with empty NPs or 2.5 μM GO-203/NPs at 0 and 72 h, and then harvested at 144 h. PD-L1 mRNA levels were determined by qRT-PCR. The results (mean ± s.e.m. of three biological replicates each performed in triplicate) are expressed as relative PD-L1 mRNA levels as compared with that obtained for the empty NP-treated cells (assigned a value of 1). (g). Mice bearing established H460 tumor xenografts (~150 mm 3 ) were treated weekly with intraperitoneal injections of empty NPs (squares) or 15 mg/kg GO-203/NPs (circles). The results are expressed as tumor volume (mean ± s.e.m., six mice per group). *P o0.05; **Po 0.01. (h) Tumors obtained on day 14 were analyzed for PD-L1 mRNA levels by qRT-PCR (left). The results (mean ± s.e.m. of three biological replicates each performed in triplicate) are expressed as relative PD-L1 mRNA levels as compared with that obtained for the tumors obtained in control mice (assigned a value of 1). Tumor lysates from empty NP-and GO-203/NP-treated mice (day 14) were immunoblotted with the indicated antibodies (right). Figures S2C and D) , further supporting the notion that the MUC1-C → NF-κB p65 pathway drives PD-L1 expression.
Supplementary Figures S2A and B). Moreover, our results show that the effects of silencing MUC1-C on PD-L1 expression (Figures 1a and b) are potentiated by adding Bay-11-7085 (Supplementary
MUC1-C/NF-κB p65 complexes occupy the CD274 promoter A potential NF-κB binding site (5′-GGGGGACGCC-3′) is located in the CD274 promoter at position − 377 to − 387 upstream to the transcription start site ( Figure 3a ). However, to our knowledge there is no available evidence showing that NF-κB occupies the CD274 promoter. Chromatin immunoprecipitation (ChIP) analysis of H1975 cell chromatin demonstrated occupancy of the CD274 promoter by NF-κB p65 (Figure 4a ). Moreover and in concert with the finding that MUC1-C binds directly to NF-κB p65, 22 re-ChIP studies demonstrated that MUC1-C forms a complex with NF-κB p65 on the CD274 promoter ( Figure 4b ). We also found that silencing MUC1-C decreases NF-κB p65 occupancy (Figure 4c) , consistent with previous studies on promoters of other NF-κB target genes, including MUC1 itself. 22 Similar results were obtained in experiments with H460 cells; that is, (i) occupancy of the CD274 promoter by NF-κB p65/MUC1-C complexes (Figures 4d and e ), and (ii) silencing MUC1-C decreases occupancy by NF-κB p65 ( Figure 4f ).
Targeting MUC1-C induces TLR7 expression by an NF-κB p65mediated mechanism Our findings that MUC1-C induces PD-L1 expression through NF-κB p65 invoked the possibility that the MUC1-C → NF-κB p65 pathway might regulate other genes involved in immune responses. However, we found that targeting MUC1-C in H1975 (Supplementary Figure S3A ) and H460 (Supplementary Figure S3B ) cells had no significant effect on PD-1, PD-L2, CTLA-4, TIM-3 and LAG-3 expression. We also investigated the potential role of MUC1-C in regulation of the TLR7 gene, which is constitutively expressed in NSCLC cells, activates the NF-κB pathway and confers chemoresistance and poor survival. [32] [33] [34] In concert with the demonstration that the TLR7 promoter is activated by NF-κB p65 (Supplementary Figure S4A ), 35 we found that targeting MUC1-C results in marked downregulation of TLR7 mRNA levels (Supplementary Figure S4B) . Moreover targeting the NF-κB pathway with Bay-11-7085 (Supplementary Figure S4C) or silencing NF-κB p65 (Supplementary Figure S4D ) was associated with decreases in TLR7 mRNA levels, indicating that, like PD-L1, the MUC1-C → NF-κB p65 pathway induces TLR7 in NSCLC cells.
MUC1-C represses immune-related genes by a ZEB1-mediated mechanism
The MUC1-C → NF-κB p65 pathway activates the ZEB1 gene, which encodes the EMT-inducing transcription factor. 36 In turn, MUC1-C interacts with ZEB1, represses miR-200c and induces EMT. 36 Based on these findings, we reasoned that the MUC1-C → NF-κB → ZEB1 pathway might link EMT with the suppression of certain immunerelated genes. As one candidate, we studied the TLR9 gene, which encodes the innate TLR9 receptor, is downregulated by NF-κB signaling 37 and has two GC-rich E-boxes as potential binding sites for MUC1-C/ZEB1 complexes (Figure 5a ). Notably, targeting MUC1-C (Figures 5b and c) was associated with marked upregulation of TLR9 mRNA levels. Moreover, silencing ZEB1 (Figure 5d , left) resulted in induction of TLR9 expression (Figure 5d, right) . ChIP and re-ChIP studies further demonstrated that ZEB1 occupies the TLR9 promoter in a complex with MUC1-C (Figures 5e and f) . Silencing MUC1-C also decreased ZEB1 occupancy on the TLR9 promoter ( Figure 5g ). Consistent with these results, analysis of TCGA and RNA-seq data sets demonstrated that MUC1 correlates negatively with TLR9 expression in NSCLCs (Supplementary Figure S5A, left and right) .
We also studied effects of targeting MUC1-C on the IFNG gene, which encodes interferon-γ (IFN-γ) and contains E-boxes in its promoter, but is not known to be regulated by ZEB1 (Figure 6a ). As shown for TLR9, silencing MUC1-C in H1975 and H460 cells induced IFN-γ expression (Figures 6b and c) . In addition, silencing ZEB1 was associated with increases in IFN-γ mRNA levels (Figure 6d ). ChIP experiments further demonstrated that (i) ZEB1 occupies the IFNG promoter in a complex with MUC1-C (Figures 6e and f) and (ii) MUC1-C promotes ZEB1 occupancy (Figure 6g ), supporting the notion that MUC1-C suppresses IFNG activation by a ZEB1-mediated mechanism. In this respect, MUC1 correlated negatively with IFN-γ expression in NSCLCs (Supplementary Figure S5B , left and right). Interestingly, IFN-γ induces CD274 transcription by a mechanism involving IRF1; 38, 39 however, our findings that MUC1-C downregulates IFN-γ and activates the CD274 promoter by occupancy with MUC1-C/NF-κB p65 complexes support a distinct pathway.
Along these same lines, we found that targeting MUC1-C and ZEB1 was associated with the upregulation of (i) MCP-1/CCL2, a key chemokine that regulates the migration and infiltration of monocytes/macrophages 40 (Figure 7a ), and (ii) GM-CSF (granulocyte-macrophage colony-stimulating factor), a key hematopoietic growth factor and immune modulator 42 (Figure 7b ), supporting the previously unexplored notion that MUC1-C/ZEB1 complexes contribute to repression of the MCP-1 and GM-CSF genes. In concert with these findings, (i) the MCP-1 gene intron 1 region has four putative ZEB1-binding sites (5′-CAGCTG-3′) at +294 to +300, +328 to +334, +400 to +406 and +616 to +622 and (ii) the GM-CSF promoter contains a potential E-box (5′-CACGTG-3′) at -1097 to -1103 relative to their transcription start sites. Additionally, like TLR9 and IFN-γ, we found that MUC1 negatively correlates with MCP-1 in NSCLCs (Supplementary Figure S5C, left and right) . In contrast, a negative correlation between MUC1 and GM-CSF was not statistically significant. Nonetheless, and in concert with these results, treatment of H460 tumors with GO-203/NPs was associated with increases in TLR9, IFN-γ, MCP-1 and GM-CSF expression (Figure 7c ), indicating that targeting MUC1-C in vivo reverses this program of immune evasion. We also found that low levels of TLR9, IFN-γ, MCP-1 and GM-CSF in the major NSCLC pathologic subtypes (GSE19188) 43 are associated with significant decreases in overall survival (Figure 7d ). Additionally, similar results were obtained from analysis of an independent data set of NSCLCs of the adenocarcinoma subtype (GSE29013) 44 ( Supplementary Figure S6) , supporting the notion that suppression of these immune-related genes in NSCLCs is associated with a poor clinical outcome.
DISCUSSION
Blockade of the PD-1/PD-L1 immune checkpoint is broadly effective in the treatment of NSCLCs and can extend survival in patients with tumors not responsive to targeted therapy. Nonetheless, PD-1/PD-L1 blockade is associated with a response rate of~20% in NSCLC and these responses can be of short duration. 3 Those findings have supported the premise that the signaling pathways responsible for induction of CD274 in NSCLCs may be integrated with the regulation of other immune-related genes. Our results demonstrate that targeting MUC1-C in NSCLC cells is effective in decreasing PD-L1 mRNA and protein. MUC1-C activates the proinflammatory TAK1 → IKK → NF-κB p65 pathway. [21] [22] [23] A critical aspect of this autoinductive circuit is that MUC1-C binds directly to NF-κB p65 and increases occupancy of NF-κB p65 on the promoters of its target genes, including MUC1 itself 22, 36 (Figure 7e ). The present results extend this circuit by demonstrating that MUC1-C forms a complex with NF-κB p65 on the CD274 promoter, increases NF-κB p65 occupancy and, in turn, activates CD274 transcription (Figure 7e ). Interestingly, activation of monocytes with lipopolysaccharide is also associated with NF-κB occupancy of the CD274 promoter, consistent with involvement of this pathway in the inflammatory response. 45 However, NF-κB has not been previously shown to occupy the CD274 promoter in cancer cells or to activate constitutively the CD274 gene, 46 supporting the importance of MUC1-C in driving The results (mean ± s.e.m. of three biological replicates each performed in triplicate) are expressed as relative mRNA levels as compared to that obtained for the CshRNA cells (assigned a value of 1). (e) Soluble chromatin from H460 cells was precipitated with anti-ZEB1 or a control IgG. (f) In the re-ChIP experiments, ZEB1 precipitates were released and then reimmunoprecipitated with anti-MUC1-C. The final DNA samples were amplified by qPCR with primers for the IFNG promoter ZEB1binding region or as a control glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The results (mean ± s.e.m. of three biological replicates each performed in triplicate) are expressed as the relative fold enrichment compared to that obtained with the IgG control (assigned a value of 1). (g) Soluble chromatin from H460/ CshRNA (left) and H460/MUC1shRNA was precipitated with anti-ZEB1 or a control IgG (right). The final DNA samples were amplified by qPCR with primers for the IFNG promoter ZEB1-binding region or as a control GAPDH. The results (mean ± s.d. of three biological replicates each performed in triplicate) are expressed as the relative fold enrichment compared with that obtained with the CshRNA cells.
the inflammatory TAK1 → IKK → NF-κB p65 pathway and thereby PD-L1 expression. Notably, our findings do not exclude the possibility that MUC1-C contributes to the regulation of PD-L1 by additional mechanisms. For instance, recent work has demonstrated that MUC1-C drives MYC in KRAS mutant NSCLC cells 47 and, by extension, MYC activates CD274 transcription. 48 Thus, in addition to the present findings, MUC1-C could regulate PD-L1 expression by alternative mechanisms that are dependent on context of the cancer cell. Indeed, the complexity of PD-L1 regulation may reflect the lack of a significant direct relationship between MUC1 and PD-L1 expression in NSCLCs.
MUC1-C associates with NF-κB p65 on the ZEB1 promoter and drives ZEB1 transcription (Figure 7e ). 36 In turn, MUC1-C binds to ZEB1 and MUC1-C/ZEB1 complexes contribute to the transcriptional suppression of miR-200c and the induction of EMT (Figure 7e ). 36 In this way, our results demonstrate that MUC1-C represses TLR9 transcription by a ZEB1-dependent mechanism (Figure 7e ). TLR9 is an innate immune receptor that recognizes unmethylated double-stranded DNA CpG motifs present in the genomes of bacteria and certain viruses. 49, 50 TLR9 is expressed in plasmacytoid dendritic cells and B cells. [49] [50] [51] Certain carcinomas also express TLR9, a finding that has linked low TLR9 levels with poor outcomes in renal and triple-negative breast cancers. 52, 53 Little is known about the regulation of TLR9 in NSCLC cells and, to our knowledge, ZEB1 is not a known suppressor of TLR9 expression. Our results support a model in which MUC1-C promotes ZEB1 occupancy of E-boxes in the TLR9 promoter and thereby suppresses TLR9 transcription (Figure 7e ). The prognostic importance of TLR9 in NSCLC is not known; however, the TLR9 immune response induces the production of type I IFNs and proinflammatory cytokines, linking innate to adaptive immunity. 54 In contrast to TLR9, other studies have demonstrated that TLR7 is overexpressed in NSCLC cells, and confers chemoresistance and poor survival. [32] [33] [34] In addition, TLR7 activates the NF-κB pathway in a positive-regulatory loop (Figure 7e ). 32, 33, 35 The present results demonstrate that MUC1-C also induces TLR7 expression by an NF-κB p65-dependent mechanism, invoking the possibility that TLR7 may contribute to the MUC1-C → NF-κB p65 autoinductive [21] [22] [23] and thereby PD-L1 expression. MUC1-C also upregulates TLR7, which contributes to NF-κB p65 activation, survival and chemoresistance of NSCLC cells. 32 MUC1-C forms a complex with NF-κB p65 and induces the activation of NF-κB target genes, including MUC1 itself, in an autoinductive circuit. 22 MUC1-C also promotes occupancy of NF-κB p65 on the ZEB1 36 and CD274/PD-L1 promoters and contributes to activation of these genes. The upregulation of ZEB1 and the formation of MUC1-C/ZEB1 complexes suppresses miR-200c and thereby induces EMT. 36 Of note, PD-L1 is also a target of miR-200, 41 invoking the possibility that the MUC1-C → NF-κB p65 → ZEB1 pathway could increase PD-L1 expression by both transcriptional and post-transcriptional mechanisms. Our results further support a role for MUC1-C/ZEB1 complexes in suppression of TLR9, IFNG, MCP-1 and GM-CSF, linking these responses with EMT. Thus, targeting MUC1-C suppresses PD-L1 and induces TLR9, IFN-γ, MCP-1 and GM-CSF expression in NSCLC tumors, supporting the notion that MUC1-C is of importance for integrating the regulation of these genes.
circuit (Figure 7e ). The findings with TLR9 and TLR7 further indicate that MUC1-C differentially regulates expression of the TLR family members.
Based on the finding that MUC1-C represses TLR9 expression, we identified other immune-related genes that are upregulated by silencing MUC1-C and have potential ZEB1-binding motifs in their promoters. Using this approach, we found that the IFNG promoter contains E-boxes and that MUC1-C/ZEB1 complexes occupy this promoter in NSCLC cells. Additionally, targeting MUC1-C decreased ZEB1 occupancy and induced IFN-γ expression. IFN-γ stimulates the JAK/STAT (Janus kinase-signal transducer and activator of transcription) pathway and induces pleotropic immune responses that activate both innate and acquired immunity. 55 In this way, IFN-γ upregulates MHC class I molecules with the enhancement of antigen priming and presentation. 56 IFN-γ also induces multiple aspects of T-helper type1-mediated immune responses by regulating the activation of T cells. 57 Moreover, IFN-γ activates macrophages and the production of chemokines that recruit effectors to inflammatory sites. 58 By extension, we found that targeting MUC1-C and ZEB1 induces (i) MCP-1, which promotes the migration and infiltration of monocytes/macrophages 40 and (ii) GM-CSF, an immune modulatory cytokine that expands granulocyte and macrophage populations, induces dendritic cell recruitment and maturation, and contributes to T-cell activation. 42 Importantly and like TLR9, we are unaware of previous findings associating ZEB1 with the repression of the IFNG, MCP-1 and GM-CSF genes.
The finding that MUC1-C activates the NF-κB p65 pathway has linked inflammation with diverse oncogenic signals that are conveyed by MUC1-C at the cell membrane and in the nucleus. 23 The interaction between MUC1-C and NF-κB p65 induces EMT through the ZEB1/miR-200c regulatory loop (Figure 7e ). 28, 36 The mesenchymal phenotype has been associated with expression of PD-L1 in NSCLCs and other carcinomas. 59, 60 The present results thus provide support for a model in which MUC1-C drives EMT and PD-L1 expression by an NF-κB p65-dependent mechanism, indicating that MUC1-C could have a pivotal role in coordinating both of these responses (Figure 7e ). In turn, our results extend this model by demonstrating that MUC1-C drives ZEB1-mediated suppression of key innate and adaptive immune-related genes and that their downregulation confers a poor prognosis for patients with NSCLC. Importantly, similar findings were obtained by targeting MUC1-C with GO-203/NPs in a NSCLC tumor xenograft model in immunocompromised mice. Based on these results, we will be studying the effects of GO-203/NPs in immunecompetent genetically engineered mouse models to assess targeting of the MUC1-C → NF-κB p65 → ZEB1 pathway and thereby immune recognition and destruction. In this respect, GO-203 has been evaluated in a phase I trial for patients with advanced malignancies, and, based on a highly favorable toxicity profile, the GO-203/NP formulation is being advanced for the treatment of patients with NSCLC and potentially in combination with immunotherapeutic agents.
MATERIALS AND METHODS
Cell culture
Human A549/KRAS(G12S), H460/KRAS(Q61H) and H1975/EGFR(L858R/ T790M) NSCLC cells (ATCC, Manassas, VA, USA) were grown in RPMI1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 μg/ml streptomycin, 100 U/ml penicillin and 2 mM L-glutamine. Authentication of the cells was performed by short tandem repeat analysis. Cells were monitored monthly for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza, Rockland, MA, USA). Cells were transfected with lentiviral vectors to stably express a scrambled CshRNA (Sigma, St Louis, MO, USA), a MUC1shRNA (Sigma), a NF-κB p65 shRNA (Sigma), MUC1-C or MUC1-C(AQA). 27, 28, 47 Puromycin and hygromycin concentrations used for optimal selection of transfected cells were determined by generating survival curves for the different cell lines. For stable transfectants, single-cell clones were identified by limiting dilution and expanded in the presence of 2 μg/ml puromycin. Cells were treated with (i) doxycycline (Sigma) and (ii) the IκB inhibitor Bay-11-7085 (Sigma) or dimethyl sulfoxide as the vehicle control. Cells were also treated with empty NPs or GO-203/NPs. 30 Quantitative real-time, reverse transcriptase PCR Whole-cell RNA was isolated using the RNeasy Mini Kit (Qiagen, Germantown, MD, USA). The High Capacity cDNA Reverse Transcription Kit (Life Technologies, Carlsbad, CA, USA) was used to synthesize cDNAs from 2 μg RNA. The GAPDH gene was used as an internal control. The SYBR Green qPCR Assay Kit and the ABI Prism Sequence Detector (Applied Biosystems, Foster City, CA, USA) were used to amplify the cDNAs. Relative mRNA expression levels were calculated using the ΔΔCt method. 61 Primers used are listed in Supplementary Table S1 .
Immunoblot analysis
Whole-cell lysates were prepared in NP-40 lysis buffer and immunoblotted with (i) anti-MUC1-C (ThermoFisher Scientific, Waltham, MA, USA; cat. no. HM-1630-P1, 1:50 dilution) and an anti-Armenian hamster secondary antibody (Abcam, Cambridge, MA, USA; cat. no. ab5745, 1:300 dilution), (ii) anti-PD-L1 (Cell Signaling Technology, Danvers, MA, USA; cat. no. 13684S, 1:1000 dilution) and an anti-rabbit secondary antibody (GE Healthcare Life Sciences, Marlborough, MA, USA; cat. no. NA934V, 1:3000 dilution) and anti-β-actin (Sigma; cat. no. A5316, 1:1000 dilution) and an anti-mouse secondary antibody (GE Healthcare Life Sciences; cat. no. NA931, 1:3000 dilution). Horseradish peroxidase secondary antibodies and enhanced chemiluminescence (GE Healthcare Life Sciences) were used for the detection of immune complexes. Immunoblot results were each confirmed with a second analysis.
Promoter-reporter assays
Cells were transfected with 1.5 μg of PD-L1 promoter-luciferase reporter (pPD-L1-Luc) or control vector (pLightSwitch_Prom; Active Motif, Carlsbad, CA, USA; cat. no. S701930) with Superfect according to the manufacturer's recommendations (Qiagen). After 48 h, lysates were analyzed using the LightSwitch Luciferase Assay Kit (Active Motif).
ChIP assays
Soluble chromatin was isolated from 3 × 10 6 cells and immunoprecipitated with anti-NF-κB p65 (Santa Cruz Biotechnology, Dallas, TX, USA) or a control immunoglobulin G (IgG) as described. 36 In re-ChIP experiments, NF-κB complexes obtained were reimmunoprecipitated with anti-MUC1-C (ThermoFisher Scientific) or a control IgG. Quantitative PCR (qPCR) analyses were performed using the SYBR Green Kit and the ABI Prism 7000 Sequence Detector (Applied Biosystems). Primers used for the CD274, TLR9 and IFNG promoters and GAPDH as a control are listed in Supplementary Table S2 . Relative fold enrichment was calculated as described. 36 NSCLC tumor xenograft studies H460 cells (5 × 10 6 ) were injected subcutaneously in the flank of 6-week old female NCR nu/nu mice. After reaching a tumor size of~150 mm 3 , mice were pair-matched in two groups and treated with empty NPs or 15 mg/kg GO-203/NPs. The formula V = L × W2/2, where L and W are the larger and smaller diameters, respectively, was used to calculate tumor volumes in an unblinded manner. These studies were performed under Protocol no. 03-029 approved by the Dana-Farber Institutional Animal Care and Use Committee.
Data analysis
Statistical significance was determined using the Student's t-test (GraphPad Software, La Jolla, CA, USA). The Shapiro-Wilk test was used to confirm normal distribution of the data (GraphPad Software).
Bioinformatic analyses
NSCLC clinical data sets were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) under the accession number (GSE72094). 23, 47, 62 GSE72084 microarray gene expression data were normalized with IRON as described. 63 TCGA data were obtained from MUC1-C integrates expression of immune-related genes
